Previous 10 | Next 10 |
Plus Therapeutics. (NASDAQ: PSTV ) +63% in-licenses novel oncology candidates. More news on: Plus Therapeutics, Inc., Bellerophon Therapeutics, Inc., Owens & Minor, Inc., Stocks on the move, , Read more ...
Athersys, Inc. (“Athersys”) (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (“Healios”), exercised in full its warrant to purchase shares of Athersys common stock. Healios purchased 4,000,000 shares at a price of $1.76 per share in accordance...
Waitr Holdings (NASDAQ: WTRH ) +70% as few consumer stocks are performing well during the rough road ahead. More news on: Waitr Holdings Inc., iFresh Inc., Biomerica, Inc., Stocks on the move, , Read more ...
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today the addition of Ms. Maia Hansen, an experienced leader in operations and supply chain management, to the Athe...
With the Coronavirus (COVID-19) wreaking havoc on the both the global economy and stock markets and most importantly, the well being of the human race , a therapy to stem the tide of the outbreak has become a high priority for the scientific community. Investors have been seeking out compan...
BioNTech SE (NASDAQ: BNTX ) +55% on teaming up with Pfizer teams to develop COVID-19 vaccine. More news on: BioNTech SE, Co-Diagnostics, Inc., Neon Therapeutics, Inc., Stocks on the move, , Read more ...
Athersys, Inc. (ATHX) Q4 2019 Earnings Conference Call March 16, 2020 4:30 PM ET Company Participants Karen Hunady – Director-Corporate Communications and Investor Relations Gil Van Bokkelen – Chairman and Chief Executive Officer Ivor Macleod – Chief Financia...
Athersys (NASDAQ: ATHX ): Q4 GAAP EPS of -$0.06 beats by $0.02 . Revenue of $0.29M (-80.8% Y/Y) beats by $0.16M . Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news, ,
Clinical trial results in Acute Respiratory Distress Syndrome (ARDS) supported Fast Track designation by FDA and designation by the Biomedical Advanced Research and Development Authority (BARDA) as a "Highly Relevant" program for COVID-19 and other pathogens Management to host c...
3 Penny Stocks To Watch Right Now The stock market saw something it hasn’t in quite some time: a full halt. At the open today, the S&P opened roughly 7% lower than its previous closing price on Friday. This triggered a circuit breaker halt for 15 minutes. This is a safeguard against...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...